Thrombotic thrombocytopenic purpura plasma replacement platelets two dozen on not go can be given immunosuppressive drugs such as cyclosporine, rituximab and immunosorbent therapy.
The prognosis of patients with thrombotic thrombocytopenic purpura after plasma exchange has been greatly improved with an overall survival rate of 70% to 80%. Immunosuppressive therapy, such as cyclosporine and rituximab, may be given to patients with acquired thrombotic thrombocytopenic purpura who do not respond well to plasma exchange.
Immunosorbent therapy can also be tried in some patients, especially in some patients associated with tumor chemotherapy, when plasma exchange and other therapies are ineffective. The procedure is to allow the patient’s plasma to be held by immunoadsorption while plasma is separated and replaced.
The diagnosis of thrombotic thrombocytopenic purpura should be standardized treatment under the guidance of a doctor to avoid blind self-medication.